MEPRO-ASPIRIN
Clinical safety rating: avoid
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
Meprobamate enhances GABAergic inhibition by binding to GABA-A receptors, increasing chloride conductance, while aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
| Metabolism | Meprobamate: hepatic via CYP2C19 and glucuronidation; aspirin: hydrolyzed to salicylic acid, conjugated with glycine (salicyluric acid) and glucuronic acid. |
| Excretion | Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylic acid). At therapeutic doses, about 10% is excreted as free salicylic acid; at toxic doses, this increases to >50%. Biliary/fecal elimination is minimal (<5%). |
| Half-life | Aspirin: 15–20 minutes (rapid hydrolysis to salicylic acid). Salicylic acid: 2–3 hours at low doses (300–600 mg), 15–30 hours at high anti-inflammatory doses (1–2 g) due to saturable metabolism. Clinically, dosing interval is adjusted based on salicylate half-life. |
| Protein binding | Aspirin: Low binding (~50% to albumin). Salicylic acid: Dose-dependent; 80–90% at low concentrations, decreasing to 30–70% at high concentrations due to saturation. Mainly bound to albumin. |
| Volume of Distribution | Aspirin: ~0.15 L/kg (small, due to rapid hydrolysis). Salicylic acid: Dose-dependent; 0.1–0.2 L/kg at therapeutic doses; increases to 0.3–0.5 L/kg at toxic doses due to saturable protein binding. Clinical meaning: Low Vd indicates distribution primarily in extracellular fluid; higher Vd at toxic levels reflects tissue penetration. |
| Bioavailability | Oral: 40–50% due to first-pass metabolism in gut wall and liver (presystemic hydrolysis). Rectal: 70–100% (avoids first-pass partially). Intravenous: 100%. |
| Onset of Action | Oral: Analgesic effect within 30–60 minutes. Rectal: Slower, 60–120 minutes. Antiplatelet effect: Within 1 hour (irreversible COX-1 inhibition). |
| Duration of Action | Analgesic/antipyretic: 3–4 hours (single dose). Anti-inflammatory: 6–12 hours (multiple doses). Antiplatelet: Lifetime of platelet (7–10 days) due to irreversible acetylation. |
| Molecular Weight | 180.16 |
Oral: 1-2 tablets (each containing 200 mg meprobamate and 325 mg aspirin) every 6 hours as needed; maximum 6 tablets per day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if GFR <30 mL/min. For GFR 30-60 mL/min: reduce dose by 50% (maximum 3 tablets per day). |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% (maximum 3 tablets per day). Child-Pugh Class C: avoid use. |
| Pediatric use | Not recommended for children under 12 years due to risk of Reye's syndrome. For adolescents (12-18 years): dose based on aspirin component; do not exceed 50 mg/kg/day of aspirin. |
| Geriatric use | Initiate at half the standard dose (maximum 3 tablets per day) due to increased risk of gastrointestinal bleeding and renal impairment. Monitor renal function and signs of bleeding. |
| 1st trimester | Avoid: associated with increased risk of miscarriage and congenital malformations (e.g., gastroschisis) due to prostaglandin synthesis inhibition. |
| 2nd trimester | Use with caution: potential risk of premature closure of ductus arteriosus and oligohydramnios; avoid chronic use. |
| 3rd trimester | Contraindicated: risk of premature closure of ductus arteriosus, oligohydramnios, and perinatal hemorrhage; may inhibit labor. |
Clinical note
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
| FDA category | Positive |
| Placental transfer | Aspirin crosses the placenta; peak fetal concentrations reach approximately 50-80% of maternal levels. |
■ FDA Black Box Warning
Combination product; meprobamate carries risk of dependence and withdrawal seizures; aspirin associated with Reye's syndrome in children with viral infections.
| Common Effects | fever |
| Serious Effects |
Hypersensitivity to aspirin or NSAIDsActive peptic ulcer diseaseHistory of asthma induced by NSAIDsSevere hepatic or renal impairmentThird trimester of pregnancyHemorrhagic diathesisConcurrent methotrexate use (>15 mg/week)
| Precautions | Risk of dependence and withdrawal from meprobamate; avoid in children/adolescents with viral illness (Reye's syndrome); bleeding risk (aspirin); impaired alertness; elderly and renal/hepatic impairment. |
| Food/Dietary | Avoid alcohol (increases CNS depression and hepatotoxicity risk). Take with food or full glass of water to reduce gastric irritation from aspirin. No specific food-drug interactions; maintain adequate fluid intake to prevent dehydration-related renal effects. |
Loading safety data…
| Breastfeeding |
| Aspirin is excreted into breast milk in low levels; however, due to theoretical risk of Reye's syndrome in infants, caution is advised. Avoid breastfeeding if using high doses or prolonged therapy. Preferred NSAIDs with shorter half-lives may be safer. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Not recommended due to risk of miscarriage and congenital malformations (e.g., gastroschisis). Second trimester: Use with caution; associated with premature closure of ductus arteriosus and oligohydramnios. Third trimester: Contraindicated after 30 weeks due to risk of premature ductus arteriosus closure and neonatal complications (e.g., persistent pulmonary hypertension). |
| Fetal Monitoring | Monitor fetal heart rate, pregnancy ultrasound for ductus arteriosus patency and amniotic fluid volume. Assess maternal blood pressure, bleeding time, and signs of gastrointestinal bleeding. |
| Fertility Effects | May impair female fertility through inhibition of prostaglandin synthesis, potentially affecting ovulation and implantation. Reversible upon discontinuation. |
| Clinical Pearls | Mepro-aspirin (meprobamate 200 mg / aspirin 325 mg) is a fixed-dose combination used historically for musculoskeletal pain with anxiety. Beware of CNS depression (additive with alcohol, benzodiazepines) and respiratory depression risk, especially in elderly or hepatic impairment. Aspirin component may cause gastric bleeding; contraindicated in children <12 years with viral illness (Reye syndrome risk). Meprobamate is habit-forming with withdrawal seizures upon abrupt discontinuation. Avoid in pregnancy (third trimester: aspirin leads to premature closure of ductus arteriosus; meprobamate has teratogenic risk). |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency due to addiction risk. · Do not drink alcohol or take other sedatives (sleeping pills, muscle relaxants) while on this medication. · Stop use and seek immediate medical attention if signs of stomach bleeding (black/tarry stools, coffee-ground vomit) occur. · Do not use in children or teenagers with chickenpox or flu-like symptoms (Reye syndrome risk). · Do not stop abruptly; taper under doctor's supervision to avoid withdrawal (anxiety, seizures). · May cause dizziness or drowsiness; avoid driving or operating machinery until effects are known. |